关键数据
1.480今开
1.496最高
1.13M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
1.25%换手率
1.480昨收
1.380最低
1.20M成交额
亏损市盈率静
2.94市净率
0.00%股息率 TTM
-24.77%ROA
3.87052周最高
0.67量比
-65.28M净利润
90.89M总股本
-0.3495每股收益TTM
2.50Beta
-68.90%ROE
0.95852周最低
7.84%振幅
86.46%毛利率
127.25M总市值
-9.90回报/风险
4.48%风险率
操作建议
Codexis Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名38/385位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.58。中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
Codexis Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Ionis Pharmaceuticals Inc
IONS
26
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
Codexis Inc简介
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代码CDXS
公司Codexis Inc
CEOMoore (Alison)
网址https://www.codexis.com/
公司股东
常见问题
Codexis Inc(CDXS)的当前股价是多少?
Codexis Inc(CDXS)的当前股价是 1.40。
Codexis Inc股票的52周最高点是多少?
Codexis Inc股票的52周最高点是3.87。
Codexis Inc股票的52周最低点是多少?
Codexis Inc股票的52周最低点是0.96。
现在Codexis Inc(CDXS)的股票是买入、持有还是卖出?
根据分析师评级,Codexis Inc(CDXS)的总体评级为买入,目标价格为6.58。
Codexis Inc(CDXS)股票的每股收益(EPS TTM)是多少
Codexis Inc(CDXS)股票的每股收益(EPS TTM)是-0.50。